for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nektar Therapeutics

NKTR.OQ

Latest Trade

21.85USD

Change

0.34(+1.58%)

Volume

447,914

Today's Range

21.76

 - 

22.98

52 Week Range

13.63

 - 

29.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
21.51
Open
22.50
Volume
447,914
3M AVG Volume
22.19
Today's High
22.98
Today's Low
21.76
52 Week High
29.99
52 Week Low
13.63
Shares Out (MIL)
177.99
Market Cap (MIL)
3,828.56
Forward P/E
-7.69
Dividend (Yield %)
--

Next Event

Q3 2020 Nektar Therapeutics Earnings Release

Latest Developments

More

Nektar Therapeutics Posts Q2 Loss Per Share Of $0.45

Nektar Therapeutics Reports First Quarter 2020 Financial Results

Nektar Therapeutics Reports Q4 Loss Per Share $0.64

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Industry

Biotechnology & Drugs

Contact Info

455 Mission Bay Blvd S

SAN FRANCISCO, CA

94158-2158

United States

+1.415.4825300

http://www.nektar.com

Executive Leadership

Robert B. Chess

Independent Chairman of the Board

Howard W. Robin

President, Chief Executive Officer, Director

Gilbert M. Labrucherie

Chief Financial Officer, Chief Operating Officer, Senior Vice President

Jillian B. Thomsen

Senior Vice President - Finance, Chief Accounting Officer

John Northcott

Senior Vice President and Chief Commercial Officer

Key Stats

2.20 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

1.2K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-0.620

2018

3.780

2019

-2.520

2020(E)

-2.803
Price To Earnings (TTM)
--
Price To Sales (TTM)
27.95
Price To Book (MRQ)
2.95
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
19.60
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-25.76
Return on Equity (TTM)
-22.73

Latest News

Latest News

Nektar Therapeutics wins dismissal of investor lawsuit over cancer drug

A federal judge has dismissed a proposed class action accusing Nektar Therapeutics Inc of misleading investors about the results of clinical trials examining the effectiveness of its flagship cancer drug.

BRIEF-Nektar Therapeutics Announces Publication Of Results From Phase 1 Dose-Escalation Study In 'Cancer Discovery' Journal

* NEKTAR THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM PHASE 1 DOSE-ESCALATION STUDY FOR BEMPEGALDESLEUKIN PLUS NIVOLUMAB IN 'CANCER DISCOVERY' JOURNAL Source text for Eikon: Further company coverage:

BRIEF-Nektar Therapeutics Reports First Quarter 2020 Financial Results

* Q1 REVENUE $50.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $47.6 MILLION

BRIEF-Nektar Therapeutics Reports Q4 Loss Per Share $0.64

* Q4 EARNINGS PER SHARE ESTIMATE $-0.68 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

Nektar withdraws application for opioid painkiller after FDA panel's vote

Nektar Therapeutics said on Tuesday it was withdrawing the application for its opioid painkiller for adults with chronic low back pain, after a U.S. Food and Drug Administration (FDA) panel unanimously voted against the drug's approval.

U.S. FDA panel votes against approval for Nektar's opioid painkiller

Independent advisers to the U.S. Food and Drug Administration on Tuesday unanimously voted against Nektar Therapeutics' opioid painkiller for adults with chronic low back pain for whom currently available therapies have been inadequate.

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

Mixed results for Bristol/Nektar combination in cancer trial

Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations.

BRIEF-Nektar Therapeutics Reports Q1 Loss Per Share $0.60

* Q1 EARNINGS PER SHARE VIEW $-0.54 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Nektar Therapeutics Says CEO Howard W. Robin's 2017 Total Compensation Was $18.1 Million

* NEKTAR THERAPEUTICS SAYS CEO HOWARD W. ROBIN'S 2017 TOTAL COMPENSATION WAS $18.1 MILLION – SEC FILING

BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors

* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS

BRIEF-Nektar Therapeutics Q4 Loss Per Share $0.21

* Q4 REVENUE $95.5 MILLION VERSUS $37.5 MILLION Source text for Eikon: Further company coverage:

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

UPDATE 1-Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement

* NEKTAR THERAPEUTICS - ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007 Source text: (http://bit.ly/2BsgSdG) Further company coverage:

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement

* NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018

BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs

BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN Source text (http://bit.ly/2zxBcXv) Further company coverage:

BRIEF-Nektar Therapeutics reports Q3 earnings per share $0.39

* Nektar Therapeutics reports financial results for the third quarter of 2017

BRIEF-Nektar Therapeutics presents preclinical data on NKTR-358

* Presents preclinical data on NKTR-358, a first-in-class regulatory T Cell stimulator, at 2017 American College of Rheumatology Annual Meeting Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up